{"name":"Inotek Pharmaceuticals Corporation","slug":"inotek-pharmaceuticals-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"trabodenoson 4.5% BID","genericName":"trabodenoson 4.5% BID","slug":"trabodenoson-4-5-bid","indication":"Treatment of glaucoma","status":"phase_3"},{"name":"trabodenoson 3.0% QD","genericName":"trabodenoson 3.0% QD","slug":"trabodenoson-3-0-qd","indication":"Treatment of glaucoma","status":"phase_3"},{"name":"trabodenoson 6.0% QD","genericName":"trabodenoson 6.0% QD","slug":"trabodenoson-6-0-qd","indication":"Treatment of glaucoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"placebo BID","genericName":"placebo BID","slug":"placebo-bid","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"timolol 0.5% BID","genericName":"timolol 0.5% BID","slug":"timolol-0-5-bid","indication":"Glaucoma","status":"phase_3"}]}],"pipeline":[{"name":"placebo BID","genericName":"placebo BID","slug":"placebo-bid","phase":"marketed","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"trabodenoson 4.5% BID","genericName":"trabodenoson 4.5% BID","slug":"trabodenoson-4-5-bid","phase":"phase_3","mechanism":"Trabodenoson is a selective adenosine receptor agonist that increases the activity of the A1 receptor.","indications":["Treatment of glaucoma"],"catalyst":""},{"name":"timolol 0.5% BID","genericName":"timolol 0.5% BID","slug":"timolol-0-5-bid","phase":"phase_3","mechanism":"Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"trabodenoson 3.0% QD","genericName":"trabodenoson 3.0% QD","slug":"trabodenoson-3-0-qd","phase":"phase_3","mechanism":"Trabodenoson is a selective adenosine A1 receptor agonist.","indications":["Treatment of glaucoma"],"catalyst":""},{"name":"trabodenoson 6.0% QD","genericName":"trabodenoson 6.0% QD","slug":"trabodenoson-6-0-qd","phase":"phase_3","mechanism":"Trabodenoson is a selective adenosine A1 receptor agonist.","indications":["Treatment of glaucoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOZXpadHNUcExIWENBLU9kQUM3WmpLMDJkeTR6akN2UlJWVkZJeUZNZ0FXcU1Jc2JTbm1MRUhPNVluQnZNRGtNWkxiYldrYndZUk1SVHpuVGNScDdwTnk1aGNTRWFfcVlMbzJpSHNPWmxucUJUb2U4eHR0WDRTaVhqbGZR?oc=5","date":"2023-10-01","type":"pipeline","source":"Massachusetts Biotechnology Council","summary":"Member Spotlight: Q&A with Catailyst - Massachusetts Biotechnology Council","headline":"Member Spotlight: Q&A with Catailyst","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9rejRTVE9jcXdRd2VUeUpNNkVSUkFxbUUtYVlvc1ZwdFVpX0tvMGVRS0FWb2hhdXRDT25BTmJfOVlja1VLVHBmU0NJdmVkSjBFeFgtc3hhWDNTeWlZdGJvTXQ4dkVPclNOc0htdA?oc=5","date":"2023-08-01","type":"regulatory","source":"Straits Research","summary":"Glaucoma Treatment Market Size, Demand, Top Share, Forecast to 2033 - Straits Research","headline":"Glaucoma Treatment Market Size, Demand, Top Share, Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5uVngwazRwVHpzNlpvWWswRFBxWkh0OG5iV3pEeGw0cXlmVlZEZzhENDU4MFFDekNRcWhFbV9Za1doYV9ldkhrRGV2YkQ2UGN1X2FkZXpUem1aZnhSNlI1UEMxdGE5WWwwSDFISHdn?oc=5","date":"2020-09-28","type":"pipeline","source":"Labiotech.eu","summary":"From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah - Labiotech.eu","headline":"From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMTZhbFUzbmMwM3lsTzByVERicTQ0NkpJdmltOGZrQzVTX3dxTWt2ZEtCaFZqYnpBV2RnQ2FOd2dMY1phcUxXeVZoWWlTUk44c2YxYUROZWJ4WHlVWTRXdkk3MjNUei0ySE1Cd3A0aWp4Wk9YSVNrTTlUTUtXQjBjRTc1NUZNdlpvVzNyb3I0NlpidzNfQzMw?oc=5","date":"2019-05-14","type":"pipeline","source":"Fortune Business Insights","summary":"Glaucoma Therapeutics Market Size, Share, Forecast, 2027 - Fortune Business Insights","headline":"Glaucoma Therapeutics Market Size, Share, Forecast, 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPdUlybU4xWllPYU9iVnNwWkxwUmNOdjhYajBwVWhGZE5EY25YN3JvRUVMRXBnVVV6MDFvWXZWQzNzZ3ItR0xoOTFJS19Ddm43ZVVoWmhjb3JXNG44ZUthSlU4eUM0aFN0WmxkVU9BU3VncE9yZkN6bnkwckVhQzJkSEp1T2tKT1VaWnM1YmxHVWdITXZ6anBJeVZlR3dteTgzd1VqbzEtc3FsX3NX?oc=5","date":"2017-09-13","type":"trial","source":"Fierce Biotech","summary":"Rocket to merge with Inotek to bag Nasdaq listing, plots gene therapy trials - Fierce Biotech","headline":"Rocket to merge with Inotek to bag Nasdaq listing, plots gene therapy trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1EeHdGYVZRNGZobzZocm9xR0RNcEhSWUJMeGZXZ3lfejhPQmdPQVhhNXA5dGROeEFQeF82NWVzb3FkQVNrSUVaOExOR1RRZlpJQUZwOUdQUmJZcl9iZDE4MnFZVXBjWUppOTRPMUN5NlNIaG1lTUc2bjE2dVdoZw?oc=5","date":"2017-07-10","type":"trial","source":"MassDevice","summary":"Inotek recalibrates after drug fails in glaucoma trial - MassDevice","headline":"Inotek recalibrates after drug fails in glaucoma trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOcUUwSW5aUldaNU9OcHVGWHN3OG5PRnVmUGdidzR6VHBpUk50T3A1LTJUcHpQRkVFTmhPZ0xEMnF1Z0VjQ2VuMEZXeFBacE1GcV9ac1pWc2xkb0V6c3VVdnhXUVYzYkkwRmlwSVVES29xMDdtTzV3X1ctRHRvM1Q3VUZ5QQ?oc=5","date":"2017-01-04","type":"pipeline","source":"BioPharma Dive","summary":"Inotek shares freefall after glaucoma drug failure - BioPharma Dive","headline":"Inotek shares freefall after glaucoma drug failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNQXNQUmRiUUFjbFFXRXlvT3kxb1FDd1htcjNrd0h3RmlTN1NFdVcyUDdQUDRvQ1ZBUFZEbE16anpuUzdPaDg1WngwTzF0Y2VEWHMtSVRnT2tDMURoaTlhT0lJQU1KNG9zcGVhM0xGNERVRjRWNFJRZDRmYjNCLUpQNXZGcVk0NDRCS0RMQXBRUHNLSnRtZ04yazROUHI?oc=5","date":"2016-06-03","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders: Big Pharma vet Sandy Macrae to helm Sangamo - Fierce Biotech","headline":"Chutes & Ladders: Big Pharma vet Sandy Macrae to helm Sangamo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNSUhDZ29QLWFRSmlZTnFWTEIweDA2OW1XVThIM1hpNU9HQlUzX2E1ZE10U3BsdWNPVlZuaDFadHpWUWhHLUE1cmlDd0JlcUFuVnRjdjdfMTJYNDFEMnZEWHE2LURBdzc5RlJsTjJ4cDcyemVGMGVuVnFyaWRpS3JQTjRyaDgtNzRt?oc=5","date":"2014-11-05","type":"pipeline","source":"24/7 Wall St.","summary":"Inotek Pharma Files for IPO - 24/7 Wall St.","headline":"Inotek Pharma Files for IPO - 24/7 Wall St.","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":1,"phase_3":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}